The latest market price of durvalumab (durvalumab) in 2026 and comparison of domestic and foreign drug purchases

Durvalumab (Durvalumab) is an anti-PD-L1 immune checkpoint inhibitor, mainly used to treat patients with non-small cell lung cancer and some urothelial cancers. According to the latest market information in January 2026, durvalumab has been launched in China, but it has not yet been included in the medical insurance reimbursement system, so patients are under great pressure to purchase the drug at their own expense. Common domestic specifications include 120mg/2.4mL and 500mg/10mL. Each box may be sold for more than 4,000 to 10,000 yuan. The specific price is affected by differences in regional hospital procurement and pharmacy pricing.

In overseas markets, the supply of durvalumab antigenic drugs is relatively mature. The common specifications are120mg/2.4mL. Each box sells for about more than one thousand US dollars, which may be equivalent to about 7,000 to 8,000 yuan in RMB (subject to exchange rate fluctuations). Although overseas prices seem higher than those in the domestic market, the medical insurance systems or drug assistance programs in some countries and regions can provide reimbursement or subsidies, and the actual out-of-pocket amount of patients may be lower than the full domestic out-of-pocket amount.

Currently, there are no generic drugs or biosimilars of imrvalumab on the market, which means that patients, whether domestic or overseas, can usually only obtain the original drug through formal medical channels and cannot rely on generic drugs to reduce costs. When used in China, due to the lack of medical insurance reimbursement, the financial burden on patients is relatively greater, and treatment costs need to be planned in advance to ensure continuous medication.

Overall, there are significant differences between domestic and foreign purchases of durvalumab. The domestic price range is wide and has not yet been reimbursed. Although the overseas price is on the high side, insurance or assistance plans can be used to reduce out-of-pocket pressure. In the future, with the development of generic drugs and adjustments to medical insurance policies, patient accessibility and affordability may further improve.

Keyword tags: durvalumab, 2025price, PD-L1 inhibitor, non-small cell lung cancer, urothelial cancer, drug purchase comparison, domestic and foreign markets, self-pay.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/31272242/